QIAGEN Expands Clinical Decision Support Software with AI-Enhanced Rare Disease Gene Coverage
QIAGEN, a leader in molecular diagnostics, has announced a significant expansion of its clinical decision support software for next-generation sequencing, QIAGEN Clinical Insight Interpret (QCI Interpret), to include artificial intelligence (AI)-enhanced coverage of thousands of rare disease genes. This development represents a significant advancement in QIAGEN's AI capabilities, which have been evolving for over two decades.
The expansion of QCI Interpret introduces several key features:
- Additional AI-Derived Literature References: QCI Interpret now incorporates AI-derived literature references for thousands of additional genes in the clinical genome. This complements the existing human-certified content curation . . .
Please subscribe for full access to all content. Access is free for the first month and $99 a month afterwards.